Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun 1;105(6):e2121-e2133.
doi: 10.1210/clinem/dgz149.

Long-Acting Growth Hormone Preparations - Current Status and Future Considerations

Bradley S Miller  1 , Eric Velazquez  1 , Kevin C J Yuen  2
Affiliations
Review

Long-Acting Growth Hormone Preparations - Current Status and Future Considerations

Bradley S Miller et al. J Clin Endocrinol Metab. .

Erratum in

Abstract

Context: Long-acting GH (LAGH) preparations are currently being developed in an attempt to improve adherence. The profile of GH action following administration of LAGH raises practical questions about clinical monitoring and long-term safety and efficacy of these new therapeutic agents.

Methods: Recent literature and meeting proceedings regarding LAGH preparations are reviewed.

Results: Multiple LAGH preparations are currently at various stages of development, allowing for decreased GH injection frequency from daily to weekly, biweekly, or monthly. Following administration of LAGH, the serum peak and trough GH and IGF-I levels vary depending upon the mechanism used to prolong GH action. Randomized, controlled clinical trials of some LAGH preparations have reported non-inferiority compared with daily recombinant human GH (rhGH) for improved growth velocity and body composition in children and adults with GH deficiency (GHD), respectively. No significant LAGH-related adverse events have been reported during short-term therapy.

Conclusion: Multiple LAGH preparations are proceeding through clinical development with some showing promising evidence of short-term clinical efficacy and safety in children and adults with GHD. The relationship of transient elevations of GH and IGF-I following administration of LAGH to efficacy and safety remain to be elucidated. For LAGH to replace daily rhGH in the treatment of individuals with GHD, a number of practical questions need to be addressed including methods of dose adjustment, timing of monitoring of IGF-I, safety, efficacy, and cost-effectiveness. Long-term surveillance of efficacy and safety of LAGH preparations will be needed to answer these clinically relevant questions.

Keywords: adult; children; growth hormone deficiency; long acting growth hormone; treatment adherence.

PubMed Disclaimer

References

    1. Savage MO, Bang P. The variability of responses to growth hormone therapy in children with short stature. Indian J Endocrinol Metab. 2012;16(Suppl 2):S178–S184. - PMC - PubMed
    1. Acerini CL, Wac K, Bang P, Lehwalder D. Optimizing patient management and adherence for children receiving growth hormone. Front Endocrinol (Lausanne). 2017;8:313. - PMC - PubMed
    1. Miller BS, Rotenstein D, Deeb LC, Germak J, Wisniewski T. Persistence with growth hormone therapy in pediatric patients. Am J Pharm Benefits. 2014;6(1):e9–e17.
    1. Kremidas D, Wisniewski T, Divino VM, et al. . Administration burden associated with recombinant human growth hormone treatment: perspectives of patients and caregivers. J Pediatr Nurs. 2013;28(1):55–63. - PubMed
    1. Holdaway IM, Hunt P, Manning P, et al. . Three-year experience with access to nationally funded growth hormone (GH) replacement for GH-deficient adults. Clin Endocrinol (Oxf). 2015;83(1):85–90. - PubMed

Publication types

MeSH terms

Substances